bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.95 USD
-0.02 (-2.17%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $0.95 0.00 (0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BLUE 0.95 -0.02(-2.17%)
Will BLUE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BLUE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLUE
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
BLUE: What are Zacks experts saying now?
Zacks Private Portfolio Services
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
Other News for BLUE
Blue Thunder Mining Reveals Rebranding and HQ Move
Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide
Bluebird Bio Announces CFO Transition and Compensation Details